| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcc7df8a0744f77b99c4e99a5d0eaf0a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 |
| filingDate |
2005-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73c71d83903b3f8eaf384908df13b04a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cf8d86a0333c2c96a05fed7caea1017
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55fd84c1504b8335518a183d46c73e5c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3f6a5d1d88dcecd4749a90cdeafb803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff4baa1d382f3a24eb4f8a0547ad710d |
| publicationDate |
2010-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2389508-C2 |
| titleOfInvention |
Anticancer combinations of cci-779 and rituximab |
| abstract |
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in treating the patients with Non Hodgkin Lymphoma. That is ensured by administration of a combination containing an effective amount of CCI-779 and rituximab in the form of a dosage form with one or more neutral components added. The combination is introduced simultaneously, separately or consistently with the other agents. ^ EFFECT: method allows improving clinical effectiveness for the given pathology, including in the patients resistant to rituximab due to synergetic interactions of these preparations. ^ 5 cl |
| priorityDate |
2004-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |